Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open Label Study to Compare the Complete Pathological Response Rate Achieved With 4 Combinations of Herceptin, Docetaxel and Pertuzumab in Patients With Locally Advanced, Inflammatory or Early Stage HER2 Positive Breast Cancer

Next Previous
X
Search
Trial Profile

A Randomized, Open Label Study to Compare the Complete Pathological Response Rate Achieved With 4 Combinations of Herceptin, Docetaxel and Pertuzumab in Patients With Locally Advanced, Inflammatory or Early Stage HER2 Positive Breast Cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 23 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pertuzumab (Primary) ; Trastuzumab (Primary) ; Docetaxel
  • Indications Advanced breast cancer; Early breast cancer; HER2 positive breast cancer; Inflammatory breast cancer
  • Focus Therapeutic Use
  • Acronyms NEOSPHERE
  • Sponsors Roche

    • Most Recent Events

    • 12 Aug 2021 Results (n=53) assessing protein expression of NRG1 in tumors and pCR rates to trastuzumab-based neoadjuvant setting as well as NRG1 gene expression in the NeoSphere trial and its relationship with pathological response, published in the Clinical Cancer Research.
    • 16 Mar 2021 According to a Roche media release, based on data from (NeoSphere, TRYPHAENA, BERENICE,CLEOPATRA ) trials, the Health Canada has granted market authorization to Perjeta (pertuzumab for injection) as a neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either >2 cm in diameter or node positive)
    • 14 Dec 2019 Results of integrated retrospective analysis assessing risk of recurrence and death after neoadjuvant systemic therapy by using data from five studies (HannaH, NeoSphere, TRYPHAENA, BERENICE, KRISTINE) presented at the 42nd Annual San Antonio Breast Cancer Symposium.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top